Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited (CLVLY) Stock Overview
Explore Clinuvel Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
333.7M
P/E Ratio
14.43
EPS (TTM)
$0.47
ROE
0.13%
CLVLY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Clinuvel Pharmaceuticals Limited (CLVLY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 45.40, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $5.05.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 14.43 and a market capitalization of 333.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.